我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

房颤并发冠心病的抗栓策略(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第2期
页码:
271-274
栏目:
综述
出版日期:
2012-04-25

文章信息/Info

Title:
Antithrombotic strategies for atrial fibrillation with coronary heart disease
作者:
魏 勇1; 刘少稳2
(上海交通大学附属第一人民医院：1.松江分院心内科，上海 201600，2.心内科，上海 200080)
Author(s):
WEI Yong1;  LIU Shao-wen2
(1.Department of Cardiology, Songjiang Branch, Shanghai 201600, 2.Department of Cardiology, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China)
关键词:
心房颤动; 冠状动脉疾病; 抗栓治疗; 卒中
Keywords:
atrial fibrillation;  coronary heart disease;  antithrombotic treatment;  stroke
分类号:
R541.75
DOI:
-
文献标识码:
A
摘要:
栓塞和血栓形成是房颤(AF)和冠心病的常见并发症，所以对于AF并发冠心病患者进行抗栓治疗就至关重要。治疗AF需要口服抗凝剂以减少缺血性卒中，而对冠心病患者则需要长期抗血小板治疗以减少冠状动脉事件。对于AF并发冠心病的患者，如何平衡抗凝或（联合）抗血小板的获益与出血风险？已成为临床讨论的焦点。本文结合2010年《ESC心房颤动治疗指南》及当前的询证学依据，详细综述了AF并发冠心病这一类栓塞高危人群的抗栓治疗策略。
Abstract:
Embolism and thrombosis are common complications of both atrial fibrillation (AF) and coronary heart disease (CHD). Antithrombotic treatment is therefore very important for patients with CHD and AF. Oral anticoagulants are critical in protecting AF patients from ischemic stroke, and long-term anti-platelet treatment is required for CHD patients to reduce coronary events. For AF patients with CHD, how to balance the benefit and the bleeding risk along with anticoagulation and/or (combined) anti-platelet treatment has become the focus of clinical discussion. In this paper, we presented a detailed overview of antithrombotic strategies for AF patients with CHD according to the ESC Guidelines for the Management of Atrial Fibrillation 2010 and current clinical evidence.

参考文献/References

[1]段卡丹,李裕舒.心房重构和炎症在心房纤颤中的意义[J].心脏杂志,2011,23(5):684-686.

[2]Camm AJ,Kirchhof P,Lip GY,et al.Guidelines for the management of atrial Fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J].European Heart Journal,2010,31(19):2369-2429.

[3]Lip GY,Nieuwlaat R,Pisters R,et al.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation[J].Chest,2010,137(2):263-272.

[4]Pisters R,Lane DA,Nieuwlaat R,et al.A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation: The Euro Heart Survey[J].Chest,2010, 138(5):1093-1100.

[5]Connolly SJ,Pogue J,Hart RG,et al.Effect of clopidogrel added to aspirin in patients with atrial fibrillation[J].N Engl J Med,2009,360(20):2066-2078.

[6]Ruiz-Nodar JM,Marín F,Hurtado JA,et al.Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneons coronary intervention and stent implantation implications for bleeding risk and prognosis[J].J Am Coll Cardiol,2008,51(8):818-825．

[7]S rensen R,Hansen ML,Abildstrom SZ,et al.Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin,clopidogrel,and vitamin K antagonists in Denmark:a retrospective analysis of nationwide registry data[J].Lancet,2009,374(9706):1967-1974.

[8]Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J].Ann Intern Med,2007,146(12):857-867.

[9]Paikin JS,Wright DS,Crowther MA,et al.Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents[J].Circulation,2010,121(18):2067-2070.

[10]何 华,马长生.是什么阻碍了我们应用华法林 [J].中国医刊,2008,48(8):4-5.

[11]熊建忠,邱 光,王心宇,等.华法林在房颤患者中的使用现状及合理应用[J].中西医结合心脑血管病杂志,2009,7(10):1233-1234.

[12]胡 凯,葛均波.心房颤动患者脑卒中预防研究进展[J].上海医学,2009,32(1):9-10.

[13]ROCKET AF Study Investigators.Rivaroxaban-Once daily,oral,direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study[J].Am Heart J,2010,159(3):340-347.

[14]Wallentin L,Yusuf S,Ezekowitz MD,et al.Efficacy and safety of dabigatran compared with warfarin at diff erent levels of international normalised ratio control for stroke prevention in atrial fi brillation: an analysis of the RE-LY trial[J].Lancet,2010, 376(9745):975-983.

备注/Memo

备注/Memo:
收稿日期：2011-07-22.通讯作者：刘少稳，教授，主要从事心脏电生理研究 Email:shaowen.liu@yahoo.com 作者简介：魏勇，博士生 Email:weiyong202@sohu.com
更新日期/Last Update: 2012-04-01